Participated · Series A · Apr 2026

ATMOS Space Cargo develops free-flying orbital transfer and re-entry vehicles (PHOENIX family) and offers space logistics services to commercial, institutional, and defence customers. PHOENIX 2 is described as a free-flying spacecraft with integrated propulsion and power capable of missions from hours to several months in LEO, performing autonomous de-orbit and controlled atmospheric re-entry using an Inflatable Atmospheric Decelerator (IAD) that is non-ablative and acts as a heat shield and aerodynamic brake. The company plans an initial three-vehicle PHOENIX 2 fleet operated as a phased campaign and is preparing recovery operations near Santa Maria in the Azores under an ANACOM licence. ATMOS is also developing PHOENIX 3, a next-generation return vehicle with an intended payload capacity of roughly one metric tonne, about ten times PHOENIX 2’s capacity. To serve governmental and defence needs it is launching ATMOS WORKS, a dedicated dual-use business unit. The company raised €25.7M in a Series A to fund these activities, including the PHOENIX 2 build, ATMOS WORKS launch, and PHOENIX 3 development, with participation from the EIC Accelerator which provides blended grant and equity financing.

Participated · Seed · Nov 2025

IDL is building a worldwide professional league that positions dance as a spectator sport, bringing together teams from multiple countries to compete in a structured season that features player contracts, major cash prizes, and championship events. Founded by the creators of STEEZY and led by CEO Connor Lim, the company blends the rigor of traditional sports with the spectacle of live entertainment to appeal to a new generation of fans. Its platform includes core competition technology and event-production infrastructure that underpins live shows and a broader digital ecosystem. The recent seed financing will allow IDL to accelerate development of this technology stack and scale its event operations. By offering standardized rules, season scheduling, and professional pathways for dancers, IDL aims to formalize dance as a mainstream sport. Although the company has not disclosed user, revenue, or audience metrics, the successful seed raise indicates investor confidence in the model and the market potential of professionalized dance.

Led · Seed · Nov 2025

Graymatter Labs Inc. is a cognitive wellness company developing plant-based products that enhance mental performance. Its flagship drink mix, Bright Mind, was formulated over 18 months with a PhD molecular biologist and blends clinically researched nootropics and adaptogens to boost focus, clarity, and brain energy within minutes without jitters or crashes. The company says it is already helping thousands of users and has earned strong unit economics and glowing customer reviews. Graymatter differentiates through its emphasis on immediate "feelability" and a broader ingredient profile than typical supplements. With fresh capital, the team will grow headcount, ramp marketing, and expand its product line into adjacent cognitive-health categories, including opportunities in elite sports. Founded by serial entrepreneur Jim Phillips (CEO) and Novisa Petrusich (CFO), Graymatter aims to make cognitive supplementation as routine as a morning cup of coffee. To date, it has secured $1.3 million in seed funding to fuel this vision.

Led · Seed · Sep 2025

Founded in 2021 in Leipzig, enaDyne combines expertise in plasma physics, catalysis, engineering, and materials science to create containerised non-thermal plasma reactors for on-site chemical synthesis. The technology integrates proprietary electrodes with plasma-active catalysts to transform CO₂ and other process gases into products such as syngas, methanol, and ethylene, while also tackling persistent pollutants like CF₄ and PFAS. Current lab results show CO₂ conversion rates above 70 % with competitive selectivities, and the equipment can be switched on and off like a light switch, enabling deployment wherever renewable electricity is available. The company’s modular architecture supports rapid scaling across industrial sites, aiming to decarbonise conventional chemical production and valorise waste CO₂. With its €7 million seed financing, enaDyne plans to build and deploy a 20-foot modular pilot plant at an industrial customer by mid-2026 and develop its first commercial plasma-based PFAS abatement product. Longer term, management targets the rollout of tens of thousands of containerised units by 2050, positioning the firm as a global platform for non-thermal plasma chemical synthesis.

Participated · Series A · Jan 2025

Quibim is a Valencia-based startup developing foundational AI models for medical imaging across oncology, immunology, neurology, and metabolic disorders. Its flagship product, QP-Prostate, is designed to improve prostate cancer detection from X-rays, CT scans, and MRIs, and the company is developing separate products for the brain, liver, breast, and lung. Quibim also offers QP-Insights for processing multi-omics data, intended for use in clinical trials and related studies. The company has FDA 510(k) clearance for QP-Prostate (2023), about 170 installations globally, and partnerships that include Stanford University and Mass General Brigham. Quibim has raised around $70 million since inception and plans to use new funding to accelerate product development and U.S. expansion. Longer-term, the company intends to create digital twins of the human body to serve dynamic models that improve diagnostic accuracy and disease understanding. QUIBIM develops QUIBIM Precision, an AI-powered radiology platform that extracts and quantifies disease-specific biomarkers from medical images to support diagnostics. The company has launched more than 20 algorithms covering conditions including cancer, Alzheimer’s, osteoarthritis and liver disease. Its products are used in over 70 hospitals and in 11 clinical trials worldwide. QUIBIM has been expanding into chest X-ray and CT scan algorithms for detecting COVID-19. The founders spun the company out of La Fe Health Research Institute in Valencia; the team’s imaging process was adopted as an industry standard by the European Society of Radiology in 2013. Following a recent capital injection, the company plans to promote new prostate, musculoskeletal and oncology solutions, expand its workforce and grow international sales and market presence. Quibim extracts quantitative imaging biomarkers from radiological and nuclear medicine images using original computational processing methods. Its core product is the Quibim Precision® cloud-based medical-imaging analysis platform, which can be deployed in private instances for hospitals and pharmaceutical companies running clinical trials. The platform processes X‑ray, ultrasound, CT, MRI and PET images with advanced algorithms including GPU processing, machine learning and big data methodologies. Quibim’s software aims to enrich diagnostic information and enable earlier assessment of pharmacological treatment response. The company is led by CEO Ángel Alberich-Bayarri and Dr. Luis Martí Bonmatí, who serves as director of the company’s Scientific Council and is a noted radiologist and director of the Clinical Imaging Area at Hospital Universitario y Politécnico La Fe. At the time of the report the team comprised 11 people; the company had previously closed a round in late 2016 and recently benefited from H2020 SME Instrument Phase II funding. Quibim (Quantitative Imaging Biomarkers in Medicine) is a medical‑imaging spin‑off from Instituto de Investigación Sanitaria La Fe, founded in 2012 and based in Valencia. The company offers a cloud analysis platform that processes radiological images and measures biomarkers of organs and tissues to enable earlier, more precise diagnoses and to evaluate early response to pharmacological treatments. The funds raised are intended to accelerate development and commercialization of that software. Quibim was founded by Ángel Alberich‑Bayarri and Dr. Luis Martí Bonmatí. The company was the first Spanish firm to receive financing from a technology‑transfer fund created within a public university.